Skip to main content
main-content

Gastroenterology

Gastroenterology

08-06-2020 | Rheumatology | News | Article

No benefit of therapeutic drug monitoring in patients starting infliximab therapy

Study results presented at the EULAR 2020 E-Congress suggest that implementing an individualized therapeutic drug monitoring strategy at the time of infliximab initiation does not improve remission rates in patients with a range of inflammatory diseases.

07-01-2020 | Rheumatology | News | Article

GI bleeding risk significantly raised in people with SSc

People with systemic sclerosis are between two and three times more likely to experience gastrointestinal bleeding than people without the autoimmune condition, research carried out in Taiwan shows.

14-10-2019 | Rheumatology | News | Article

IBS an ‘overlooked’ comorbidity in axSpA patients

Around a third of individuals with axial spondyloarthritis exhibit gut-related symptoms characteristic of irritable bowel syndrome, finds an analysis of a population-based study.

17-01-2019 | Oncology | News | Article

Mixed results for watch-and-wait strategy in rectal cancer

Although a watchful waiting approach to rectal cancer surgery is associated with a high rate of rectal preservation among patients who achieve a clinical complete response after neoadjuvant therapy, it may adversely affect survival and also distant control in certain patients, suggests data from a case series.

14-08-2018 | Oncology | News | Article

Preoperative antivirals lower recurrence risk in HBV-related liver cancer

Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.

03-08-2018 | HBV | News | Article

HCC risk score developed for patients with chronic hepatitis B virus

Researchers have developed and validated a score for predicting the risk for hepatocellular carcinoma in Asian patients with chronic hepatitis B virus infection who are taking oral antiviral therapy.

03-08-2018 | HBV | News | Article

HCC risk remains even after achieving positive HBV outcomes

Two meta-analyses published in the Journal of Viral Hepatitis confirm that patients with hepatitis B virus infection remain at risk for hepatocellular carcinoma even after achieving positive virologic outcomes, and identify factors associated with the risk.

03-08-2018 | HBV | News | Article

Global HBV prevalence estimated at 3.9%

More than 290 million people, or 3.9% of the global population, are infected with hepatitis B virus, and while efforts to combat infection are improving, greater access to diagnosis and treatment is needed to meet global targets, report The Polaris Observatory Collaborators.

03-05-2018 | HBV | News | Article

Updated AASLD guidance released on HBV prevention, diagnosis, and treatment

The American Association for the Study of Liver Diseases has issued a guidance statement for chronic hepatitis B virus, covering topics ranging from screening and prevention through to the clinical management of patients.

03-05-2018 | HBV | News | Article

End of treatment HBsAg levels may predict HBV relapse

Hepatitis B surface antigen levels at the end of treatment or prophylaxis with nucleos(t)ide analog inhibitors could be a useful indicator of hepatitis B virus relapse, suggest two Taiwanese studies.

03-05-2018 | HBV | News | Article

‘Excellent’ survival with long-term TDF, entecavir treatment of chronic HBV

Caucasian patients with chronic hepatitis B virus infection who receive long-term therapy with tenofovir disoproxil fumarate or entecavir have “excellent” survival, which is comparable to that of the general population, say researchers.

05-04-2018 | Gastrointestinal cancer | News | Article

Treating H. pylori reduces metachronous gastric cancer risk

Antibiotic therapy for Helicobacter pylori in patients with early gastric cancer is associated with a 50% lower risk for subsequent disease, trial findings indicate.

01-02-2018 | HBV | News | Article

ACP, CDC issue HBV vaccination, screening best practice advice

The American College of Physicians and Centers for Disease Control and Prevention have released best practice guidance for hepatitis B virus vaccination, screening, and linkage to care.

01-02-2018 | HBV | News | Article

Diabetes linked to elevated HCC risk after HBsAg seroclearance

Diabetes remains an independent risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection even after hepatitis B surface antigen seroclearance, findings indicate.

01-02-2018 | HBV | News | Article

Estimates of HBV carrier numbers in Japan released

Japanese researchers have generated a nationwide estimate of total numbers of hepatitis B virus carriers and treated patients in 2011, comparing it with earlier estimates from 2000.

29-01-2018 | Oncology | News | Article

Lutetium-177–dotatate granted US approval for GEP-NETs

Read more on this FDA announcement here

22-12-2017 | HBV | News | Article

FIB-4 index identifies chronic HBV patients with lowest HCC risk

The noninvasive fibrosis-4 index can further refine the existing favorable clinical profile for hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B virus infection and help identify those with the lowest risk, say researchers.

22-12-2017 | HBV | News | Article

Serum HBV RNA may represent noninvasive marker for HBV progression

Serum hepatitis B virus RNA levels correlate with viral transcriptional activity and histologic changes in the livers of patients with chronic HBV who are receiving nucleos(t)ide analog therapy, Chinese researchers report.

15-12-2017 | HBV | News | Article

Durability of HBsAg clearance induced by NA therapy demonstrated

Clearance of hepatitis B surface antigen with nucleos(t)ide analogs is as durable as spontaneous clearance in patients with chronic hepatitis B virus infection, researchers report.

15-12-2017 | HBV | News | Article

HBV remains major contributor to primary liver cancer globally

Hepatitis B virus infection is the leading cause of incident primary liver cancer and associated mortality worldwide, according to research published in JAMA Oncology.

Image Credits